JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, M. R.
Right arrow Articles by Anderson, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, M. R.
Right arrow Articles by Anderson, C. J.

In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy

Michael R. Lewis, PhD1, Mu Wang, MD1, Donald B. Axworthy, BS2, Louis J. Theodore, PhD2, Robert W. Mallet, BS2, Alan R. Fritzberg, PhD2, Michael J. Welch, PhD1 and Carolyn J. Anderson, PhD1

1 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
2 NeoRx Corporation, Seattle, Washington



View larger version (21K):

[in a new window]
  		FIGURE 1. Biodistributions of 1.1 MBq (30 µCi) of NR-LU-10/SA–pretargeted 64Cu-DOTA-biotin in SW1222-bearing nude mice at 2 h (A) and 24 h (B) after injection, administered at doses of 0.5, 1.0, 2.0, and 5.0 µg of compound.

 


View larger version (13K):

[in a new window]
  		FIGURE 2. Tumor and blood time–activity curves of 64Cu-DOTA-NR-LU-10 (A) and NR-LU-10/SA–pretargeted 64Cu-DOTA-biotin (B) in SW1222-bearing nude mice. Note difference in y-axis scales.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.